TPM2: ONE-YEAR REHOSPITALISATION RATE IN SCHIZOPHRENIA AND SCHIZOAFFECTIVE DISORDER

AbstractAccording to ICD 10, nonorganic hypersomnia is defined as “a condition of either excessive daytime sleepiness and sleep attacks (not accounted for by an inadequate amount of sleep) or prolonged transition to the fully aroused state upon awakening. When no definite evidence of organic etiology can be found, this condition is usually associated with mental disorders”. The severe hypersomnia in the course of schizoaffective disorder is rather a rare phenomenon. The paper presents the case of 41-year-old female patient with severe hypersomnia during the course of the schizoaffective disorder. The course of hypersomnia was severe. The patient slept constantly day and night and was awoken by her family for about three-hour period of time. The duration of hypersomnia was about one year until the onset of treatment. The patient was successfully treated with light therapy that caused gradual resolution of the symptoms of hypersomnia. The patient is also treated as prior to the onset of hypersomnia with antipsychotics and the mood stabilizers for schizoaffective disorder. Since that time there were six-year-period of follow up when the patient was free of any symptoms of hypersomnia.

Download Full-text

Remission in schizophrenia: one-year Italian prospective study of risperidone long-acting injectable (RLAI) in patients with schizophrenia or schizoaffective disorder

Human Psychopharmacology Clinical and Experimental ◽

10.1002/hup.1067 ◽

2009 ◽

Vol 24 (7) ◽

pp. 574-583 ◽

Cited By ~ 20

Author(s):

Alessandro Rossi ◽

Anna Bagalà ◽

Vincenzo Del Curatolo ◽

Francesco Scapati ◽

Micaela Maria Bernareggi ◽

...

Keyword(s):

Prospective Study ◽

Schizoaffective Disorder ◽

One Year ◽

Long Acting

Download Full-text

Treatment with intramuscular paliperidone palmitate in schizoaffective disorder

European Psychiatry ◽

10.1016/j.eurpsy.2016.01.2156 ◽

2016 ◽

Vol 33 (S1) ◽

pp. S581-S581

Author(s):

L. Maroto Martin ◽

P. Hervías Higueras

Keyword(s):

Schizoaffective Disorder ◽

Complex Disease ◽

Psychotic Disorders ◽

Paliperidone Palmitate ◽

Valuable Treatment ◽

History Of ◽

Competing Interest ◽

One Year ◽

Long Acting ◽

Monthly Dose

IntroductionInjectable formulations of long acting antipsychotic are a valuable treatment option for patients with psychotic disorders. Schizoaffective Disorder (SAD) is a complex disease; the optimal treatment is not well established yet.ObjectiveAnswer the question about the effectiveness offered by intramuscular Paliperidone Palmitate in SAD versus other injectable antipsychotics. Keywords: schizoaffective disorder; paliperidone palmitate injection.MethodsA case report of a 35-year-old male diagnosed with Schizoaffective Disorder six years ago and with personal history of multiple manic decompensation after treatment discontinuation. Throughout his life he has been treated with intramuscular Risperidone 87.5 mg (50 + 37.5) every 14 days, Olanzapine flas 20 mg/day, Risperidone flas 3 mg, Amisulpride 600 mg/day, Valproic acid 1500 mg/day Clonazepam 2 mg/day and Lormetazepam 1 mg. In the last admission one year ago, he started treatment with intramuscular paliperidone palmitate up to 200 mg a month. Currently he receives a monthly dose of 100 mg and concomitant lithium 800 mg/day.DiscussionThe use of intramuscular paliperidone palmitate in SAD and its effectiveness against other injectable antipsychotic is discussed.ConclusionsThe use of intramuscular paliperidone palmitate appears to constitute an employment opportunity in the treatment of intramuscular maintenance in SAD. It could be effective in stabilizing episodes of acute exacerbation and remissions of psychotic, manic and depressive symptoms.Disclosure of interestThe authors have not supplied their declaration of competing interest.

Download Full-text

Schizoaffective Disorder in a Fragile-X Carrier

Australian & New Zealand Journal of Psychiatry ◽

10.1046/j.1440-1614.1999.00564.x ◽

1999 ◽

Vol 33 (3) ◽

pp. 436-440 ◽

Cited By ~ 9

Author(s):

Yousef Al-Semaan ◽

Ashok K. Malla ◽

Andrea Lazosky

Keyword(s):

Complete Remission ◽

Executive Functions ◽

Social Functioning ◽

Schizoaffective Disorder ◽

Clinical Picture ◽

Initial Treatment ◽

Antipsychotic Drugs ◽

Fragile X ◽

Female Carrier ◽

One Year

Objective: Here we report the case of a schizoaffective psychosis in a female carrier of fragile-X (CGG sequence > 200). Clinical picture: The patient presented with symptoms of psychosis (hallucinations, delusions and disorganised thinking) and mania, preceded by decline in intellectual and social functioning. Treatment and outcome: Initial treatment with antipsychotic drugs alone or in combination with sodium valproate was only partially effective, but the addition of lithium resulted in a complete remission. Conclusions: One year later the patient presented predominantly with deficit symptoms and profound deficits in memory and executive functions. It is likely that the intellectual deterioration around the time of puberty associated with fragile-X increased her vulnerability to a schizoaffective disorder and eventually to poor functioning.

Download Full-text

Olanzapine versus haloperidol in the treatment of schizoaffective disorder

The British Journal of Psychiatry ◽

10.1192/bjp.174.1.15 ◽

1999 ◽

Vol 174 (1) ◽

pp. 15-22 ◽

Cited By ~ 43

Author(s):

Pierre V. Tran ◽

Gary D. Tollefson ◽

Todd M. Sanger ◽

Yili Lu ◽

Paul H. Berg ◽

...

Keyword(s):

Weight Gain ◽

Adverse Events ◽

Maintenance Therapy ◽

Schizoaffective Disorder ◽

International Study ◽

Double Blind ◽

Additional Improvement ◽

One Year ◽

Term Maintenance

BackgroundThe effectiveness of antipsychotic monotherapy in schizoaffective disorder is limited, and further constrained by safety concerns.AimsWe aimed to compare the efficacy, tolerability and safety profile of the new pharmaceutical, olanzapine, with haloperidol.MethodData were assessed from 300 DSM – III – R schizoaffective subjects from a larger double-blind prospective international study. Subjects were randomly allocated to six weeks of olanzapine (5–20 mg) or haloperidol (5–20 mg) treatment; responders were followed for up to one year of double-blind, long-term maintenance therapy.ResultsOlanzapine-treated patients achieved a statistically significant greater improvement than haloperidol-treated patients on overall measures of efficacy, including clinical response. Significantly fewer olanzapine patients left the study early, and fewer adverse events were observed among those receiving olanzapine. During maintenance, olanzapine-treated patients continued to experience additional improvement, with fewer EPS but more weight gain than those on haloperidol.ConclusionsOlanzapine demonstrated substantial advantages over the conventional antipsychotic haloperidol in the management of schizoaffective disorder.

Download Full-text

Switching treatment-resistant patients with schizophrenia or schizoaffective disorder to olanzapine: a one-year open-label study with five-year follow-up

Current Medical Research and Opinion ◽

10.1185/030079903125002108 ◽

2003 ◽

Vol 19 (6) ◽

pp. 473-480 ◽

Cited By ~ 7

Author(s):

James L. Karagianis ◽

Kellie K. LeDrew ◽

Daniel J. Walker

Keyword(s):

Schizoaffective Disorder ◽

Treatment Resistant ◽

Open Label ◽

Open Label Study ◽

Label Study ◽

One Year ◽

Switching Treatment

Download Full-text

P.3.c.067 One year study: efficacy of haloperidol versus risperidone in the treatment of schizoaffective disorder

European Neuropsychopharmacology ◽

10.1016/s0924-977x(10)70737-9 ◽

2010 ◽

Vol 20 ◽

pp. S496-S497

Author(s):

D. Siladji Mladenovic ◽

S. Drezgic Vukic ◽

B. Golubovic ◽

A. Ivezic

Keyword(s):

Schizoaffective Disorder ◽

One Year

Download Full-text

Factors Influencing Rehospitalisation of Patients with Schizophrenia in Japan: A 1-year Longitudinal Study

Hong Kong Journal of Occupational Therapy ◽

10.1016/j.hkjot.2016.10.002 ◽

2016 ◽

Vol 28 (1) ◽

pp. 7-14 ◽

Cited By ~ 4

Author(s):

Takeshi Shimada ◽

Ai Nishi ◽

Tomotaka Yoshida ◽

Sachie Tanaka ◽

Masayoshi Kobayashi

Keyword(s):

Longitudinal Study ◽

Occupational Therapy ◽

Outpatient Treatment ◽

Clinical Characteristics ◽

Contributing Factors ◽

Factors Influencing ◽

One Year ◽

Assessment Scales ◽

Preliminary Support ◽

Rehospitalisation Rate

Objective/Background This longitudinal study explored factors influencing the rehospitalisation of patients with schizophrenia in Japan. Methods Participants comprised patients with schizophrenia who were discharged from a psychiatric hospital in Japan. The investigations were conducted at the time of discharge and one year later. Demographics and clinical characteristics included the following: the type of occupational therapy (OT) interventions (group and individualized or group only); the assessment scales’ scores on hospitalisation; the community living conditions after discharge; and the contents of outpatient treatment (outpatient OT, day-care treatment, home-visit nursing, and adherence to outpatient treatment and medication). All variables were examined in a binomial logistic regression analysis to identify the factors for rehospitalisation. Results The rehospitalisation rate was 31.8%, as 14 of 44 participants were rehospitalised within one year after discharge. The type of OT interventions (OR = 7.05, 95% CI = 1.36 −36.69, p = .020) and the adherence to outpatient treatment and medication (OR = 9.48, 95% CI = 1.82–49.33, p = .008) were significant contributing factors to rehospitalisation. Conclusion This study provided preliminary support for the finding that individualized occupational therapy and proper adherence to outpatient treatment and medication are associated with reducing the rehospitalisation of patients with schizophrenia in Japan.

Download Full-text

Between ‘Savage Man’ and ‘Most Faithful Englishman’ Manteo and the Early Anglo-Indian Exchange, 1584–1590

Itinerario ◽

10.1017/s0165115300044545 ◽

2000 ◽

Vol 24 (2) ◽

pp. 146-169 ◽

Cited By ~ 1

Author(s):

Michael Leroy Oberg

Keyword(s):

North Carolina ◽

Chesapeake Bay ◽

One Year ◽

Anglo Indian

In August of 1587 Manteo, an Indian from Croatoan Island, joined a group of English settlers in an attack on the native village of Dasemunkepeuc, located on the coast of present-day North Carolina. These colonists, amongst whom Manteo lived, had landed on Roanoke Island less than a month before, dumped there by a pilot more interested in hunting Spanish prize ships than in carrying colonists to their intended place of settlement along the Chesapeake Bay. The colonists had hoped to re-establish peaceful relations with area natives, and for that reason they relied upon Manteo to act as an interpreter, broker, and intercultural diplomat. The legacy of Anglo-Indian bitterness remaining from Ralph Lane's military settlement, however, which had hastily abandoned the island one year before, was too great for Manteo to overcome. The settlers found themselves that summer in the midst of hostile Indians.

Download Full-text